Related Experiment Video
Updated: Mar 6, 2026
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
7.1K
Perspective on precision medicine in paediatric heart failure
Michael D Fridman1, Seema Mital2
1Division of Cardiology, Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada M5G 1X8.
Clinical Science (London, England : 1979)
|March 8, 2017
Summary
Precision medicine offers a promising approach to treating pediatric heart failure, a complex genetic condition. This research highlights the need for integrated studies to develop targeted therapies for better patient outcomes.
Area of Science:
- Cardiology
- Genetics
- Precision Medicine
Background:
- Pediatric heart failure affects 1 in 100,000 children and is often genetic.
- Current treatments address symptoms, not the underlying causes of pediatric heart failure.
- There is a critical need for targeted therapies for pediatric heart failure.
Purpose of the Study:
- To explore the application of precision medicine in pediatric heart failure.
- To advocate for integrated research approaches in pediatric cardiology.
Main Methods:
- Leveraging the Precision Medicine Initiative (PMI) framework.
- Integrating multi-omics data (genomics, proteomics, metabolomics, transcriptomics, phenomics).
- Considering lifestyle and social factors alongside biological data.
Main Results:
- Precision medicine techniques show potential for studying rare and complex pediatric diseases.
- Coordinated research in multiple fields can lead to novel therapeutic and prognostic applications.
- This approach can improve care for children with heart failure.
Conclusions:
- Precision medicine can significantly benefit pediatric heart failure research.
- Integrated research efforts are crucial for advancing pediatric cardiology.
- Targeting the root causes of pediatric heart failure will reduce morbidity and mortality.
Related Concept Videos
01:30Heart Failure V: Medical Management
441
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
441
01:29Cardiomyopathy V: Interprofessional Care
558
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
558
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
588
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
588
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
56
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
56
01:29Heart Failure II: Pathophysiology
1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
01:17Pathophysiology of Heart Failure
4.2K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.2K